Dashboard
Manage Tickers

AFMDAffimed N.V.

Nasdaq affimed.com


$ 3.92 $ 0.00 (0 %)    

Thursday, 12-Sep-2024 09:30:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 468.45 $ -0.18 (-0.04 %)
DIA $ 409.66 $ 0.20 (0.05 %)
SPY $ 554.86 $ -0.13 (-0.02 %)
TLT $ 100.19 $ -0.18 (-0.17 %)
GLD $ 234.60 $ -0.04 (-0.02 %)
$ 3.85
$ 3.92
$ 3.82 x 500
-- x --
$ 3.92 - $ 3.92
$ 2.24 - $ 8.95
38,167
na
58.63M
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-affimed
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:46:53

Cantor Fitzgerald analyst Li Watsek reiterates Affimed (NASDAQ:AFMD) with a Overweight.

hc-wainwright--co-reiterates-buy-on-affimed-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Affi...
09/06/2024 10:21:06

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:AFMD) with a Buy and maintains $10 price t...

as-of-june-30-2024-affimeds-cash-cash-equivalents-and-investments-were-344m-based-on-operating-and-financial-plans-cash-runway-projected-into-h2-2025
As Of June 30, 2024, Affimed's Cash, Cash ...
09/05/2024 10:36:40

affimed-q2-2024-gaap-eps-101-misses-096-estimate-sales-154000k-compared-to-139m-yoy
Affimed Q2 2024 GAAP EPS €(1.01) Misses €(...
09/05/2024 10:35:25

affimed-appoints-shawn-m-leland-as-chief-executive-officer
Affimed Appoints Shawn M. Leland As Chief ...
09/03/2024 11:48:46

laidlaw--co-maintains-buy-on-affimed-raises-price-target-to-25
Laidlaw & Co. Maintains Buy on Affimed, Ra...
06/13/2024 14:23:37

Laidlaw & Co. analyst Yale Jen maintains Affimed (NASDAQ:AFMD) with a Buy and raises the price target from $15 to $25.

hc-wainwright--co-reiterates-buy-on-affimed-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Affi...
06/13/2024 10:18:14

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:AFMD) with a Buy and maintains $10 price t...

affimed-anticipates-cash-equivalents-and-short-term-investments-to-support-operations-into-h2-2025
Affimed Anticipates Cash, Equivalents And ...
06/12/2024 10:35:23

affimed-q1-eps-138-beats-154-estimate-sales-16834k-miss-134m-estimate
Affimed Q1 EPS $(1.38) Beats $(1.54) Estim...
06/12/2024 10:34:03

Affimed (NASDAQ:AFMD) reported quarterly losses of $(1.38) per share which beat the analyst consensus estimate of $(1.54) by 10...

why-is-german-biotech-affimed-stock-soaring-on-monday
Why Is German Biotech Affimed Stock Soarin...
06/03/2024 18:13:08

Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate a...

why-science-applications-international-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Science Applications International Sha...
06/03/2024 17:56:53

why-affimed-shares-are-soaring
Why Affimed Shares Are Soaring
06/03/2024 16:58:38

Affimed shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 stud...

affimed-shares-resume-trade
Affimed Shares Resume Trade
06/03/2024 16:35:15

affimed-shares-halted-on-circuit-breaker-to-the-upside-stock-now-up-821
Affimed Shares Halted On Circuit Breaker T...
06/03/2024 16:30:41

hc-wainwright--co-reiterates-buy-on-affimed-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Affi...
06/03/2024 11:29:08

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:AFMD) with a Buy and maintains $10 price t...

affimed-announced-saturday-in-17-egfr-wild-type-nsclc-patients-who-failed-chemotherapy-and-pd-1pd-l1-afm24-plus-atezolizumab-achieved-4-objective-responses-3-of-4-responses-were-ongoing-for-more-than-7-months-progression-free-survival-was-59-months
Affimed Announced Saturday, In 17 EGFR Wil...
06/02/2024 18:43:54

affimed-says-fda-granted-fast-track-designation-to-combination-of-its-innate-cell-engager-afm24-with-atezolizumab-for-egfr-wild-type-non-small-cell-lung-cancer
Affimed Says FDA Granted Fast Track Design...
05/29/2024 10:32:25

This is for the treatment of patients with advanced and/or metastatic non-small cell lung cancer (NSCLC) not harboring any acti...

affimed-announces-acceptance-of-an-abstract-on-preclinical-data-of-its-innate-cell-engager-afm28-at-the-eha-2024-congress
Affimed Announces Acceptance Of An Abstrac...
05/14/2024 14:12:48

Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid ...

affimed-announces-acceptance-of-afm24-clinical-abstract-for-egfr-wildtype-egfrwt-non-small-cell-lung-cancer-nsclc-at-the-2024-annual-meeting-of-the-american-society-of-clinical-oncology
Affimed Announces Acceptance of AFM24 Clin...
04/24/2024 08:08:34

wells-fargo-maintains-overweight-on-affimed-lowers-price-target-to-25
Wells Fargo Maintains Overweight on Affime...
04/01/2024 15:37:33

Wells Fargo analyst Yanan Zhu maintains Affimed (NASDAQ:AFMD) with a Overweight and lowers the price target from $30 to $25.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION